PIK3CA and colorectal carcinoma: Consistent with the preclinical data, an exploratory analysis of time on treatment and progression free survival suggests that PIK3CA-mutant CRC patients may derive greater benefit from this treatment strategy as compared to PIK3CA WT CRC patients20.